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Sir,
The prevalence of migraine in chil-
dren and adolescents under 18 years
is rising, and by age 15, 75% of chil-
dren will experience a significant
headache [1]. Although studies show
that migraine headaches remit in
17%–34% of adolescent subjects,
headaches persist in 20%–48% of
subjects, and transform into other
types of headaches in 11%–37%. In a
recent study of 55 subjects aged
11–14 with migraine headaches at
baseline, 38.2% had experienced
remission, but 41.8% had persistent
migraine and 20.0% transformed to
tension-type headache [2]. Misunder-
standing and inadequate treatment
can add to the disabling burden of
migraine. This causes loss of school,
social and valuable extracurricular
participation in a subset of patients.
Compounding the problem is the lack
of FDA-approved triptan therapies in
patients less than 18 years old, in
spite of numerous articles demon-
strating the effectiveness of triptans
[3]. Both central and peripheral com-
ponents of the trigeminal pain path-
way play a significant role in the
symptoms and signs of the migraine
attack. Triptans are the most effective





order neurons and other brainstem
generators have become centrally
sensitised and refractory in many
adults. Welch et al. [5] found that iron
deposition occurs in the periaqueduc-
tal grey (PAG) in patients with fre-
quent migraines that evolved into
chronic migraine. Kruit and col-
leagues [6] studied 435 adults with
migraine±aura and controls utilising
MRI imaging and found the risk of
higher white matter lesion burden on
MRI increased with increasing attack
frequency. Burstein and Jakubowski
demonstrated that central sensitisa-
tion explains the progression of
attacks, but also may play a role in the
progression of the disease itself.
Repeated central sensitization
episodes are associated with perma-
nent neuronal damage, preventative
treatment refractoriness and disease
progression [7].
Many adults with chronic daily
headache not due to medication
overuse did not receive abortive or
preventative treatment by a headache
expert at onset in childhood and ado-
lescence. Preventative (prophylactic)
treatment works best if instituted
prior to the development of daily
headache patterns [8]. Effective,
aggressive and early pharmacological
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treatment of the young migraineur in
the early stage of headache presenta-
tion will not only reduce headache
disability, but may be the venue for
migraine disease modification.
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